Cowen analyst Chris Shibutani weighed in on Puma Biotechnology (NASDAQ: PBYI) saying the AdCom documents 'appear neutral'.Shibutani said the absence ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE